Study treatment not supplied by BMS will be stored in accordance with the package insert. IP documentation (whether supplied by BMS or not) must be maintained including all processes required to ensure that treatment is accurately administered. This includes documentation of drug storage, administration, and, as applicable, stora ge temperatures, reconstitution, and use of required processes (eg, required diluents and administration sets). Further guidance and information for final disposition of unused study tr eatment are provided in Appendix 2 and the pharmacy manual. 7.4.1 Retained Samples for Bioavailability / Bioequivalence Not applicable. 7.5 Treatment Compliance Study treatment w ill be administered in the clinical facility by trained medical pers onnel. Treatment compliance will be monitored by drug accountability as well as by recording BMS-986226, nivolumab, and ipilimumab administration in participants’ medical records and in the CRF. 7.6 Concomitant Therapy 7.6.1 Prohibited and/or Restricted Treatments Prohibited and/or restricted medications taken prior to study tr eatment admin istration in the study are described below. Medications taken within 4 weeks prior to study tr eatment admin istration must be recorded on the CRF. The following medications are prohibited during th e study (unless utilized to treat a drug-related AE): •Immunosuppressive agents (except as stated in Section 7.6.2 ) •Concurrent anti-neoplastic therapy (ie, chemotherapy, hormonal therapy (except where otherwise indicate), immunotherapy, extensive, non-palliative radiation therapy, or standard or investigational agents) Herbal prescriptions including, but not limited to, cannabis and other recreational drugs •Any live / attenuated vaccine (eg varicella, zoster, yellow fever, rotavirus, oral polio and measles, mumps, rubella (MMR) during treatment and until 100 days post last dose. No concomitant medications (prescription, over-the -counter or herbal) are to be administered during the study unless they are prescribed for the tr eatment of specific clinical events. Any concomitant therapies must be recorded on the CRF. Revised Protocol No.: 04 Date: 31-May-2019 91 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS 7.6.1.1 Imaging Restriction and Precautions It is the local imaging fa cility’s respons ibility to determine, based on par ticipant attributes (eg, allergy history, diabetic history, and renal status), the appropriate imaging modality and contrast regimen for each participant. Imaging contraindications and contrast risks s hould be considered in this assessment.